Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

Jumat, 02 Oktober 2026 - 21:27:28 Wib
Globenewswire

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Jumat, 02 Oktober 2026 - 21:26:38 Wib
Globenewswire

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

Kamis, 01 Oktober 2026 - 22:51:45 Wib
Globenewswire

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Selasa, 29 September 2026 - 22:34:15 Wib
Globenewswire

Teva Releases Q3 2026 Aide Memoire

Kamis, 24 September 2026 - 22:18:05 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Kamis, 24 September 2026 - 22:17:25 Wib
Globenewswire

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Senin, 21 September 2026 - 20:24:09 Wib
Globenewswire

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Senin, 21 September 2026 - 20:23:18 Wib
Globenewswire

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Senin, 21 September 2026 - 20:22:15 Wib
Globenewswire

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

Rabu, 16 September 2026 - 22:54:54 Wib
Globenewswire

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Senin, 14 September 2026 - 21:28:13 Wib
Globenewswire

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Kamis, 10 September 2026 - 22:48:27 Wib
Globenewswire

Teva Announces Launch of Offering of Senior Notes

Senin, 07 September 2026 - 23:13:42 Wib
Globenewswire

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Jumat, 04 September 2026 - 22:48:00 Wib
Globenewswire

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Rabu, 02 September 2026 - 21:48:55 Wib
Globenewswire

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

Rabu, 02 September 2026 - 21:39:07 Wib
Globenewswire

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

Selasa, 01 September 2026 - 22:16:20 Wib
Globenewswire

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

Ahad, 30 Agustus 2026 - 20:13:14 Wib
Globenewswire

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Rabu, 19 Agustus 2026 - 21:48:36 Wib
Globenewswire

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Selasa, 11 Agustus 2026 - 21:24:55 Wib
Globenewswire

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Rabu, 29 Juli 2026 - 20:52:00 Wib
Globenewswire

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Kamis, 09 Juli 2026 - 22:23:52 Wib
Globenewswire

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Selasa, 07 Juli 2026 - 21:38:30 Wib
Globenewswire

Teva Releases Q2 2026 Aide Memoire

Jumat, 19 Juni 2026 - 22:07:17 Wib
Globenewswire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Jumat, 19 Juni 2026 - 22:06:43 Wib